Named Patient Medicines

  In a clinical trial, half of patients with metastatic colon or rectal cancer treated with LONSURF® (trifluridine and tipiracil) Tablets were still alive at 7.1 months and half of patients who received placebo were still alive at 5.3 months were alive. Worsening of disease or death occurred in 88% of patients treated with LONSURF and 94% of patients receiving placebo. In the clinical trial, half of the patients with metastatic colon cancer treated with LONSURF were still alive at 5.7 months and half of the patients who received placebo were still alive at 3.6 months. Worsening of disease or death occurred in 85% of patients treated with LONSURF and 92% of patients receiving placebo.   Signs and important safety information LONSURF is a prescription medicine used to treat adults • Colorectal cancer that has spread to other parts of the body and has been previously treated or cannot receive certain chemotherapy drugs. • A type of stomach cancer called gastric cancer, includ